Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer.
TILs
immune checkpoints
immune heterogeneity
metastatic lesions
ovarian cancer
platinum-sensitivity
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Aug 2019
26 Aug 2019
Historique:
received:
04
08
2019
accepted:
14
08
2019
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
29
8
2019
Statut:
epublish
Résumé
CD3
Identifiants
pubmed: 31455033
pii: cancers11091250
doi: 10.3390/cancers11091250
pmc: PMC6769550
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 16EX1021N
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Lancet Oncol. 2016 Jan;17(1):78-89
pubmed: 26590673
Cancer Immunol Res. 2016 Nov;4(11):948-958
pubmed: 27688020
Oncotarget. 2016 Nov 1;7(44):71123-71135
pubmed: 27661102
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Am J Pathol. 2013 Aug;183(2):576-91
pubmed: 23885715
Clin Cancer Res. 2017 Jul 1;23(13):3453-3460
pubmed: 27986748
Cell. 2017 Aug 24;170(5):927-938.e20
pubmed: 28841418
Cancers (Basel). 2018 Jul 26;10(8):null
pubmed: 30049987
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
J Ovarian Res. 2018 May 30;11(1):43
pubmed: 29843813
J Pathol. 2017 Jan;241(1):57-66
pubmed: 27741368
Gastroenterology. 1996 Dec;111(6):1433-46
pubmed: 8942721
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
J Natl Cancer Inst. 2000 May 3;92(9):699-708
pubmed: 10793106
Cancers (Basel). 2018 Oct 18;10(10):null
pubmed: 30340430
Curr Oncol. 2017 Dec;24(6):e540-e546
pubmed: 29270064
Trends Immunol. 2017 Jul;38(7):526-536
pubmed: 28579319
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Oncotarget. 2017 Feb 28;8(9):15621-15631
pubmed: 28152503
Virchows Arch. 2011 Aug;459(2):183-91
pubmed: 21713364
Oncotarget. 2017 Feb 14;8(7):12389-12405
pubmed: 27852039
Ann Oncol. 2016 Jan;27(1):114-21
pubmed: 26487588
Cancer Res. 2013 Jan 1;73(1):119-27
pubmed: 23108141
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Int J Gynecol Cancer. 2018 May;28(4):729-737
pubmed: 29498983
Int J Gynecol Pathol. 2011 Jul;30(4):366-71
pubmed: 21623201
Cancer Cell. 2016 Apr 11;29(4):587-601
pubmed: 27070705
Oncotarget. 2018 Apr 3;9(25):17501-17511
pubmed: 29707124
Front Oncol. 2017 Feb 22;7:24
pubmed: 28275576
J Pathol. 2013 Sep;231(1):21-34
pubmed: 23780408
Cancers (Basel). 2019 Jan 03;11(1):null
pubmed: 30609853
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
pubmed: 24078660
Endocr Relat Cancer. 2018 May;25(5):R303-R318
pubmed: 29487129
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
Genome Res. 2014 Feb;24(2):200-11
pubmed: 24221193
Memo. 2016;9:82-84
pubmed: 27429660
Oncotarget. 2018 Apr 27;9(32):22832-22849
pubmed: 29854318
Oncotarget. 2017 Dec 4;8(70):114935-114944
pubmed: 29383131
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Int J Cancer. 2018 Jul 1;143(1):8-15
pubmed: 29218796
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Clin Cancer Res. 2014 Nov 1;20(21):5384-91
pubmed: 25204552
Virchows Arch. 2012 May;460(5):455-65
pubmed: 22527018
Cell Death Dis. 2018 Jul 10;9(7):766
pubmed: 29991744
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92
pubmed: 17161157
Gynecol Oncol Res Pract. 2016 Nov 24;3:11
pubmed: 27904752